Literature DB >> 21247221

Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence.

Tharaka Dassanayake1, Patricia Michie, Gregory Carter, Alison Jones.   

Abstract

BACKGROUND: Many individuals in the community are prescribed psychoactive drugs with sedative effects. These drugs may affect their daily functions, of which automobile driving is a major component.
OBJECTIVE: To examine the association of three classes of commonly used psychoactive drugs (viz. benzodiazepines and newer non-benzodiazepine hypnotics, antidepressants and opioids) with (i) the risk of traffic accidents (as indexed by epidemiological indicators of risk); and (ii) driving performance (as indexed by experimental measures of driving performance).
METHODS: A literature search for material published in the English language between January 1966 and January 2010 in PubMed and EMBASE databases was combined with a search for other relevant material referenced in the retrieved articles. Retrieved articles were systematically reviewed, carrying out meta-analyses where possible. Twenty-one epidemiological studies (13 case-control and 8 cohort studies) fulfilled the inclusion criteria by estimating the accident risk associated with drug exposure (ascertained by blood/urine analysis or prescription records). Sixty-nine experimental studies fulfilled the inclusion criteria by testing actual or simulated driving performance after administering a single dose or multiple doses.
RESULTS: Two meta-analyses showed that benzodiazepines are associated with a 60% (for case-control studies: pooled odds ratio [OR] 1.59; 95% CI 1.10, 2.31) to 80% (for cohort studies: pooled incidence rate ratio 1.81; 95% CI 1.35, 2.43) increase in the risk of traffic accidents and a 40% (pooled OR 1.41; 95% CI 1.03, 1.94) increase in 'accident responsibility'. Co-ingestion of benzodiazepines and alcohol was associated with a 7.7-fold increase in the accident risk (pooled OR 7.69; 95% CI 4.33, 13.65). Subgroup analysis of case-control studies showed a lower benzodiazepine-associated accident risk in elderly (>65 years of age) drivers (pooled OR 1.13; 95% CI 0.97, 1.31) than in drivers <65 years of age (pooled OR 2.21; 95% CI 1.31, 3.73), a result consistent with age-stratified risk differences reported in cohort studies. Anxiolytics, taken in single or multiple doses during the daytime, impaired driving performance independent of their half-lives. With hypnotics, converging evidence from experimental and epidemiological studies indicates that diazepam, flurazepam, flunitrazepam, nitrazepam and the short half-life non-benzodiazepine hypnotic zopiclone significantly impair driving, at least during the first 2-4 weeks of treatment. The accident risk was higher in the elderly (>65 years of age) who use tricyclic antidepressants (TCAs); however, the evidence for an association of antidepressants with accident risk in younger drivers was equivocal. Sedative but not non-sedative antidepressants were found to cause short-term impairment of several measures of driving performance. Limited epidemiological research reported that opioids may be associated with increased accident risk in the first few weeks of treatment.
CONCLUSIONS: Benzodiazepine use was associated with a significant increase in the risk of traffic accidents and responsibility of drivers for accidents. The association was more pronounced in the younger drivers. The accident risk was markedly increased by co-ingestion of alcohol. Driving impairment was generally related to plasma half-lives of hypnotics, but with notable exceptions. Anxiolytics, with daytime dosing, impaired driving independent of their half-lives. TCAs appeared to be associated with increased accident risk, at least in the elderly, and caused short-term impairment in driving performance. Opioid users may be at a higher risk of traffic accidents; however, experimental evidence is limited on their effects on driving.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21247221     DOI: 10.2165/11539050-000000000-00000

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  85 in total

1.  Use of self-controlled analytical techniques to assess the association between use of prescription medications and the risk of motor vehicle crashes.

Authors:  Jack E Gibson; Richard B Hubbard; Christopher J P Smith; Laila J Tata; John R Britton; Andrew W Fogarty
Journal:  Am J Epidemiol       Date:  2009-01-30       Impact factor: 4.897

Review 2.  Effects of antidepressants on cognitive functions: a review.

Authors:  I Amado-Boccara; N Gougoulis; M F Poirier Littré; A Galinowski; H Lôo
Journal:  Neurosci Biobehav Rev       Date:  1995       Impact factor: 8.989

3.  Studies of clobazam and car-driving.

Authors:  B Biehl
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

4.  Medazepam and the driving ability of anxious patients.

Authors:  N C Moore
Journal:  Psychopharmacology (Berl)       Date:  1977-03-23       Impact factor: 4.530

5.  Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance.

Authors:  Joris C Verster; Edmund R Volkerts; Antonia H C M L Schreuder; Erik J E Eijken; Janet H G van Heuckelum; Dieuwke S Veldhuijzen; Marinus N Verbaten; Isabelle Paty; Mona Darwish; Philippe Danjou; Alain Patat
Journal:  J Clin Psychopharmacol       Date:  2002-12       Impact factor: 3.153

6.  Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers.

Authors:  S Otmani; A Demazières; C Staner; N Jacob; T Nir; N Zisapel; L Staner
Journal:  Hum Psychopharmacol       Date:  2008-12       Impact factor: 1.672

7.  Alcohol interaction of lormetazepam, mepindolol sulphate and diazepam measured by performance on the driving simulator.

Authors:  H P Willumeit; H Ott; W Neubert; K G Hemmerling; M Schratzer; K Fichte
Journal:  Pharmacopsychiatry       Date:  1984-03       Impact factor: 5.788

8.  The effects of two antidepressants, imipramine and viloxazine, upon driving performance.

Authors:  A B Clayton; P G Harvey; T A Betts
Journal:  Psychopharmacology (Berl)       Date:  1977-11-24       Impact factor: 4.530

9.  Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam.

Authors:  Ingebjørg Gustavsen; Jørgen G Bramness; Svetlana Skurtveit; Anders Engeland; Ineke Neutel; Jørg Mørland
Journal:  Sleep Med       Date:  2008-01-28       Impact factor: 3.492

10.  Mirtazapine, a sedating antidepressant, and improved driving safety in patients with major depressive disorder: a prospective, randomized trial of 28 patients.

Authors:  Jianhua Shen; Henry J Moller; Xuehua Wang; Sharon A Chung; Gilla K Shapiro; Xiuying Li; Colin M Shapiro
Journal:  J Clin Psychiatry       Date:  2009-01-13       Impact factor: 4.384

View more
  68 in total

1.  Measurement of adherence to clinical practice guidelines for opioid therapy for chronic pain.

Authors:  Amanda M Midboe; Eleanor T Lewis; Meenah C Paik; Rollin M Gallagher; Jack M Rosenberg; Francine Goodman; Robert D Kerns; William C Becker; Jodie A Trafton
Journal:  Transl Behav Med       Date:  2012-03       Impact factor: 3.046

Review 2.  Deprescribing Benzodiazepines in Older Patients: Impact of Interventions Targeting Physicians, Pharmacists, and Patients.

Authors:  Brendan J Ng; David G Le Couteur; Sarah N Hilmer
Journal:  Drugs Aging       Date:  2018-06       Impact factor: 3.923

3.  Latent Classes of Polydrug Users as a Predictor of Crash Involvement and Alcohol Consumption.

Authors:  Michael Scherer; Eduardo Romano; Robert Voas; Eileen Taylor
Journal:  J Stud Alcohol Drugs       Date:  2018-05       Impact factor: 2.582

4.  Depression and Alzheimer's Disease Biomarkers Predict Driving Decline.

Authors:  Ganesh M Babulal; Suzie Chen; Monique M Williams; Jean-Francois Trani; Parul Bakhshi; Grace L Chao; Sarah H Stout; Anne M Fagan; Tammie L S Benzinger; David M Holtzman; John C Morris; Catherine M Roe
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

5.  High-intensity drinking and nonmedical use of prescription drugs: Results from a national survey of 12th grade students.

Authors:  Sean Esteban McCabe; Philip Veliz; Megan E Patrick
Journal:  Drug Alcohol Depend       Date:  2017-06-29       Impact factor: 4.492

6.  Inappropriate benzodiazepine use in elderly patients and its reduction.

Authors:  Cara Tannenbaum
Journal:  J Psychiatry Neurosci       Date:  2015-05       Impact factor: 6.186

7.  Sedative-hypnotic medicines and falls in community-dwelling older adults: a cost-effectiveness (decision-tree) analysis from a US Medicare perspective.

Authors:  Cara Tannenbaum; Vakaramoko Diaby; Dharmender Singh; Sylvie Perreault; Mireille Luc; Helen-Maria Vasiliadis
Journal:  Drugs Aging       Date:  2015-04       Impact factor: 3.923

8.  Screening to identify signals of opioid drug interactions leading to unintentional traumatic injury.

Authors:  Charles E Leonard; Colleen M Brensinger; Thanh Phuong Pham Nguyen; John R Horn; Sophie Chung; Warren B Bilker; Sascha Dublin; Samantha E Soprano; Ghadeer K Dawwas; David W Oslin; Douglas J Wiebe; Sean Hennessy
Journal:  Biomed Pharmacother       Date:  2020-07-30       Impact factor: 6.529

9.  Residual effects of low-dose sublingual zolpidem on highway driving performance the morning after middle-of-the-night use.

Authors:  Annemiek Vermeeren; Eric F P M Vuurman; Tim R M Leufkens; Cees J Van Leeuwen; Anita C M Van Oers; Eugene Laska; Salvador Rico; Frank Steinberg; Thomas Roth
Journal:  Sleep       Date:  2014-03-01       Impact factor: 5.849

Review 10.  Medication use and the risk of motor vehicle collisions among licensed drivers: A systematic review.

Authors:  Toni M Rudisill; Motao Zhu; George A Kelley; Courtney Pilkerton; Brandon R Rudisill
Journal:  Accid Anal Prev       Date:  2016-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.